Pharmx Update: Interview with the CEO

Deepening our understanding

Pharmx (PHX.AX) is our biggest position.

If you’ve never heard about the company before, please read our deep dive first.

Last week, we sat down with Tom Culver, the CEO of Pharmx.

As usual, we prepared more questions than we had time to ask.

Tom gave a lot of additional color to what is happening inside the company, and our understanding of the business has grown once more.

And some of the information was revealing:

This is why we’ll only be able to grow our top line by 20 to 30% per year instead of 50%.

We try to get in touch with the management of all our holdings to delve deeper into each business case. All premium members get direct access to this kind of deeper due diligence.

Let’s go through the full Q&A.